Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Ondansetron for treating alcohol-use disorder TS ID 11884Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC